Publication: The inhibitory effect of 13-butoxyberberine bromide on migration in breast cancer MDA-MB-231 cells
| dc.contributor.author | Laomethakorn P. | |
| dc.contributor.author | Jaitrong M. | |
| dc.contributor.author | Samosorn S. | |
| dc.contributor.author | Watanapokasin R. | |
| dc.date.accessioned | 2021-04-05T03:02:53Z | |
| dc.date.available | 2021-04-05T03:02:53Z | |
| dc.date.issued | 2019 | |
| dc.date.issuedBE | 2562 | |
| dc.description.abstract | Background: 13-butoxyberberine bromide is a berberine derivative that has not been reported on the anti-migration mechanism of breast cancer. Cancer metastasis is the major cause of cancer mortality, about 90% of cancer patients death are caused by cancer metastasis not the primary tumor. Therefore, the compound that could inhibit cancer migration is necessary for development as anti-cancer drug. Objective: To investigate the effects of 13-butoxyberberine bromide on the anti-migration of breast cancer MDA-MB-231 cells. Materials and Methods: Cell viability was determined by MTT assay. Wound-healing assay and transwell chamber assay were used to determine cell migration. Protein expression levels were examined by western blot analysis. Results: 13-Butoxyberberine bromide at sub-toxic concentration (10 μg/mL) inhibited cell migration in MDA-MB-231 treated cells via down-regulation of MMP-2 and MMP-9 expression which play important role in cancer cell metastasis. Conclusion: 13-Butoxyberberine bromide at 10 μg/mL showed anti-migration effect against MDA-MB-231 cells through inhibition of mediator proteins. These findings could be useful in the development of 13-butoxyberberine bromide to be a novel anti-migration agent for clinical use in the future. © Journal Of The Medical Association Of Thailand| 2019. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.citation | Journal of the Medical Association of Thailand. Vol 102, No.7 (2019), p.12-16 | |
| dc.identifier.issn | 1252208 | |
| dc.identifier.other | 2-s2.0-85070210485 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14740/5219 | |
| dc.rights.holder | มหาวิทยาลัยศรีนครินทรวิโรฒ | |
| dc.subject.other | 13 butoxyberberine bromide | |
| dc.subject.other | Berberine derivative | |
| dc.subject.other | Beta actin | |
| dc.subject.other | Chemoattractant | |
| dc.subject.other | Gelatinase A | |
| dc.subject.other | Gelatinase B | |
| dc.subject.other | Proteinase inhibitor | |
| dc.subject.other | Unclassified drug | |
| dc.subject.other | Article | |
| dc.subject.other | Breast cancer | |
| dc.subject.other | Cell migration | |
| dc.subject.other | Cell migration assay | |
| dc.subject.other | Cell survival | |
| dc.subject.other | Cell viability | |
| dc.subject.other | Chemoluminescence | |
| dc.subject.other | Controlled study | |
| dc.subject.other | Down regulation | |
| dc.subject.other | Human | |
| dc.subject.other | Human cell | |
| dc.subject.other | MDA-MB-231 cell line | |
| dc.subject.other | Metastasis | |
| dc.subject.other | Microscopy | |
| dc.subject.other | Migration inhibition | |
| dc.subject.other | MTT assay | |
| dc.subject.other | Protein expression level | |
| dc.subject.other | Transwell chamber assay | |
| dc.subject.other | Western blotting | |
| dc.subject.other | Wound healing assay | |
| dc.title | The inhibitory effect of 13-butoxyberberine bromide on migration in breast cancer MDA-MB-231 cells | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| swu.datasource.scopus | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070210485&partnerID=40&md5=c2f323af647ff770e880c7729323edf1 |
